MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering price per share of $10.50. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses ...